Baxter completes acquisition of Claris Injectables for $625 million

Baxter International Inc. completed the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company, for approximately $625 million, gaining three manufacturing plants and over 50 products.

“Baxter International Inc. today announced the completion of the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company.”baxter.com.pl

• 2 sources
• baxter.com.plBaxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio | BaxterJul 27, 2017
• biopharmadive.comClosing Claris deal, Baxter set to invest in three new plants | BioPharma DiveJacob BellAug 3, 2017

Summarized from public sources; check the original articles before acting on it.